Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CASI Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $7.16. CASI Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 13.38 Mil. Therefore, CASI Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $95.79 Mil.
CASI Pharmaceuticals's quarterly market cap
increased
from Jun. 2023 ($33.30 Mil) to Sep. 2023 ($34.25 Mil) and
increased
from Sep. 2023 ($34.25 Mil) to Dec. 2023 ($95.79 Mil).
CASI Pharmaceuticals's annual market cap
declined
from Dec. 2021 ($111.84 Mil) to Dec. 2022 ($24.09 Mil) but then
increased
from Dec. 2022 ($24.09 Mil) to Dec. 2023 ($95.79 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CASI Pharmaceuticals's Enterprise Value for Today is $23.17 Mil.
CASI Pharmaceuticals Market Cap Historical Data
The historical data trend for CASI Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CASI Pharmaceuticals's Market Cap
For the Biotechnology subindustry, CASI Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's Market Cap falls into.
CASI Pharmaceuticals Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CASI Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (NAS:CASI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CASI Pharmaceuticals Market Cap Related Terms
Thank you for viewing the detailed overview of CASI Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CASI has been successfully added to your 